MK2206 was administered as a second-line therapy to patients with advanced NSCLC accompanied by brain metastases, and the data showed that patients with EGFR mutations have a longer median progression-free survival (PFS) than those with wild-type EGFR (15.2 months vs 4.4 months/NCT00663689) [162]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.